| Similar Articles |
|---|
 |
The Motley Fool
January 12, 2007
Brian Lawler |
What's Next for Northfield Labs? When Northfield released results from its phase 3 trial for PolyHeme, its shares fell almost 60% in one day. But Northfield again said it's not giving up on PolyHeme and would eventually apply to the FDA to market the drug.   |
Chemistry World
May 14, 2009
Rebecca Trager |
Bloodshed for blood substitute makers The synthetic blood business has taken a hit as regulators pan products and two major players are brought to the brink of collapse. |
The Motley Fool
May 24, 2007
Brian Lawler |
Learn From Northfield's Bloody Results Northfield announces clinical trial results that investors can learn from. As long as they at least give the appearance of trying to advance their compounds forward, development-stage drugmakers can go on for years always getting investor funding from somewhere. |
The Motley Fool
October 11, 2006
Brian Lawler |
Waiting on Northfield The development-stage drug company waits for clinical trial results. Until the fate of its lead product is known, most of Northfield's financial results will be of peripheral importance to investors at best. |
The Motley Fool
May 1, 2007
Brian Lawler |
Northfield Delays the Inevitable Northfield announces a delay in the analysis of a clinical trial for its drug candidate. Investors, take note. |
Chemistry World
May 1, 2008
Rebecca Trager |
Blood Substitutes Pose Worrying Risks Oxygen-carrying blood substitutes currently in clinical trials are associated with a much higher likelihood of serious adverse events such as heart attack and death. |
The Motley Fool
July 10, 2006
Brian Lawler |
Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced. |
The Motley Fool
January 10, 2007 |
The Trials of Northfield Labs: Fool by Numbers The pharmaceutical released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
September 26, 2007
Brian Lawler |
Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures. |
Chemistry World
October 2010 |
Artificial blood Synthetic alternatives to donor blood have been stuck in development for decades. Nina Notman reports on recent promising progress |
Popular Mechanics
December 16, 2008
Michael Milstein |
Bringing Stem Cells to War: Meet the Blood Pharmers Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery. |
The Motley Fool
June 29, 2004
Charly Travers |
Antegren Gets Priority Review The FDA steps up the drug's time line for approval. |
Wired
August 2002
Wil McCarthy |
Strange Blood Cataclysmic shortages. Tainted supplies. There is a solution: artificial blood. |
Reason
July 2004
Caroline Waters |
Bloody Shame Unnecessary regulations are making American blood banks run dry. |
Salon.com
September 14, 2000
David Tuller |
Seeing red Gay men have long been infuriated by a government ban on their donating blood. This week the FDA is reconsidering its position. |
